Evidence map›Paper›PMID 42205117›Full record

ArticleInternational journal of pharmaceutics: X2026

Intravitreal faricimab pharmacokinetics assessed by PET imaging in a neovascular Age-related Macular Degeneration rat model.

Xurxo García-Otero, Andrea Cuartero-Martínez, Patricia Fernández-Robredo, Soraya Groba-de Antas, Noemí Gómez-Lado, Francisco J Otero-Espinar, María Hernández, Jaione Bezunartea, Alfredo García-Layana, Sergio Recalde and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xurxo García-OteroMolecular Imaging and Pharmacokinetic Modelling Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Spain.
Andrea Cuartero-MartínezFarmaCHUSLab Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Patricia Fernández-RobredoOphthalmology Experimental Laboratory, Navarra Institute for Health Research (IdiSNA), University of Navarra, Pamplona, Spain.
Soraya Groba-de AntasMolecular Imaging and Pharmacokinetic Modelling Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Spain.
Noemí Gómez-LadoMolecular Imaging and Pharmacokinetic Modelling Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Spain.
Francisco J Otero-EspinarDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain.
María HernándezOphthalmology Experimental Laboratory, Navarra Institute for Health Research (IdiSNA), University of Navarra, Pamplona, Spain.
Jaione BezunarteaOphthalmology Experimental Laboratory, Navarra Institute for Health Research (IdiSNA), University of Navarra, Pamplona, Spain.
Alfredo García-LayanaOphthalmology Experimental Laboratory, Navarra Institute for Health Research (IdiSNA), University of Navarra, Pamplona, Spain.
Sergio RecaldeOphthalmology Experimental Laboratory, Navarra Institute for Health Research (IdiSNA), University of Navarra, Pamplona, Spain.
Pablo AguiarMolecular Imaging and Pharmacokinetic Modelling Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Spain.
Anxo Fernández-FerreiroFarmaCHUSLab Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age-related Macular Degeneration (AMD) is the leading cause of blindness in the elderly, with its neovascular form characterised by abnormal vessel growth. Current anti-VEGF therapies require frequent intravitreal injections and show variable efficacy. Faricimab, a novel bispecific antibody targeting VEGF-A and ANG-2, offers a dual mechanism with the potential for enhanced efficacy and extended dosing intervals. This study aimed to characterise the intravitreal pharmacokinetics, biodistribution, and ocular localization of faricimab in a rat model of laser-induced choroidal neovascularization (CNV) using non-invasive molecular imaging. Faricimab was conjugated with DFO and radiolabelled with zirconium-89 ([

Indexed as

Anti-ANG-2Anti-VEGFBiodistributionCNV modelFaricimabPharmacokinetics

Identifiers

PMID42205117
PMCPMC13202531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.